Conjugated estrogens and Elexacaftor, tezacaftor, and ivacaftor interaction
Conjugated estrogens and Elexacaftor, tezacaftor, and ivacaftor: the Elexacaftor, tezacaftor, and ivacaftor prescribing label describes an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Elexacaftor, tezacaftor, and ivacaftor (Trikafta) label · effective 2026-06-22
For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives.
Following the resolution of rash, consider resuming TRIKAFTA without the hormonal contraceptives.
If rash does not recur, resumption of hormonal contraceptives can be considered.
Hormonal contraceptives may play a role in the occurrence of rash and cannot be excluded [see Adverse Reactions (6.1) ] .
Hormonal Contraceptives TRIKAFTA has been studied with ethinyl estradiol/levonorgestrel and was found to have no clinically relevant effect on the exposures of the oral contraceptive.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.